CXCL10 is highly expressed in mouse models of plasmacytoma and mammary adenoma, while it has low expression in mouse models without thymus; therefore, the anti-tumor effect of the CXCL10/CXCR3 pathway is thought to be T lymphocyte-dependent (100). This evidence concerns the gene CXCL10 and neoplasm.